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COMMENTS AND RESPONSES
Barriers to Herpes Zoster Vaccination
TO THE EDITOR: Hurley and colleagues (1) showed that the major
barriers that keep physicians from using the herpes zoster vaccine are
the cost concerns of their patients and their own worries about
freezer storage of the vaccine. These barriers may have resulted in low
vaccine uptake. With respect to these findings, we would like to
make some comments based on our prospective questionnaire study
in the Netherlands (2). In our primary care study, we assessed the
willingness of elderly patients to accept free herpes zoster vaccination
simultaneously with their annual influenza vaccination. The partici-
pating primary care physicians were equipped free of charge with
adequate storage facilities. In all, only 39% of the invited patients
accepted the herpes zoster vaccination, whereas 76% accepted the flu
vaccination. The major determinants of nonadherence with the her-
pes zoster vaccination were perceived lack of recommendation by the
physician, unwillingness to adhere to the physician’s advice, and the
perception of low risk for herpes zoster. These results show that
removing the issues of cost and freezer storage space, which Hurley
and colleagues identified, may not lead to desirable rates of herpes
zoster vaccination. To increase the acceptance of vaccination, more
information is needed for both patients and physicians about the
effect of herpes zoster in elderly persons and about the efficacy and
cost-effectiveness of the vaccine. Furthermore, in Europe, a
refrigerator-stable herpes zoster vaccine that can be stored at temper-
atures between 2 °C and 8 °C has been registered. This may end the
need for freezer storage (3).
Wim Opstelten, MD, PhD
Gerrit A. van Essen, MD, PhD
University Medical Center Utrecht
3584CX Utrecht, the Netherlands
Eelko Hak, MSc, PhD
University of Groningen
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IN RESPONSE: We thank Dr. Opstelten and colleagues for their
comments and agree that solving the financial and freezer storage
issues we discovered would not remove all barriers to herpes zoster
vaccine uptake in the United States. However, the results of our
study and those of Opstelten and colleagues’ study (1) differ in a few
important ways that make direct comparison problematic. First, Op-
stelten and colleagues’ study was done in the Netherlands, and the
herpes zoster vaccine was not recommended there at that time; there-
fore, physicians and patients were probably not familiar with it. Our
study was done in the United States at a time when the herpes zoster
vaccine had been recommended for almost 2 years. Second, health
care systems and financing of care differ between the Netherlands
and the United States in ways that may markedly affect population
responses. Third, the study by Opstelten and colleagues (1) presents
the patient perspective, whereas our study presents the provider per-
spective. Although we did not find the perceived lack of serious
sequelae from herpes zoster and postherpetic neuralgia to be a major
barrier to administering herpes zoster vaccine to providers, U.S. pa-
tients could perceive it as a larger barrier. The 2007 National Im-
munization Survey—Adult (2), which provides some insight into the
patient perspective of herpes zoster vaccination in the United States,
found that 77.8% of respondents who had not yet received the
herpes zoster vaccine would accept it (hypothetically) if recom-
mended by their physician. It would be interesting to do a study in
the United States similar to that of Opstelten and colleagues, where
patients would have the option of receiving the herpes zoster vaccine
for free, rather than theorizing on what patients might do if offered
it, as in the National Immunization Survey—Adult survey.
We agree with Dr. Opstelten and colleagues that greater aware-
ness of herpes zoster vaccine in patients may lead to greater accep-
tance. Patients in the United States are probably less aware of the
herpes zoster vaccine than of other routinely recommended vaccines
because the manufacturer has had supply constraints and, as a result,
the vaccine has not been actively promoted in the United States. Dr.
Opstelten and colleagues also note that a refrigerator-stable herpes
zoster vaccine (3) has been registered in Europe, which is another
crucial issue. Besides the herpes zoster vaccine, the other varicella-
containing vaccines have been available in international markets in
refrigerator-stable formulations (4). Hopefully, these vaccines will
become available in the United States, because the requirement for
freezer storage is an important barrier to all vaccine programs.
Laura Hurley, MD, MPH
Denver Health
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Important Differences in Measurement of Fetuin-A
TO THE EDITOR: Parker and colleagues (1) found no significant
association between fetuin-A levels and mortality in a cohort with
prevalent coronary artery disease. Our understanding of fetuin-A
biology is greatly undermined by the lack of agreement among dif-
ferent methods of measurement. It is therefore particularly important
that method descriptions are unambiguous. The authors comment
that their nephelometric fetuin-A assay “uses the same high-
specificity antibody as commercially available enzyme-linked immu-
nosorbent assays.” It is unclear to which commercially available as-
says they are referring—the 2 most widely used commercial kits not
only use different antisera but also use a sandwich format with 2
different antibodies that recognize spatially distinct molecular
epitopes. This statement implies a degree of equality with other
methods that we have not found to be the case (2). The authors
justify use of this method by referring to a study (3) in which use of
the same fetuin-A assay showed an association between fetuin-A lev-
els and mortality in patients receiving hemodialysis. However, it does
not necessarily follow that this method is powered to detect signifi-
cant associations in other settings, associations that may be masked
by a lack of specificity to the biologically relevant fraction.
The poor agreement between commercial assays for fetuin-A
does not represent a mere analytical nuance but has critical implica-
tions for observations derived from their measurements. For exam-
ple, in a cohort of patients with mild-to-moderate chronic kidney
disease, we showed that fetuin-A was an independent predictor of
progressive aortic stiffness (4), a vascular variable known to be pre-
dictive of cardiovascular events and mortality. This relationship was
lost, even in simple bivariate correlation, by measuring fetuin-A with
an alternative assay. Our experiments suggest that the lack of agree-
ment in both chronic kidney disease as well as non–chronic kidney
disease settings reflects variation in antibody specificity for different
glycosylated forms of fetuin-A (2). Although Parker and colleagues
correctly acknowledge that “results may differ with other assays,” it
remains a relatively unappreciated point that differences in antibody
specificity to different modified forms of the same protein (a heter-
ogeneous mixture) can mask potentially important associations. In
the case of fetuin-A, have the investigators considered further study
using alternative methodology?
Edward R. Smith, MSc, PhD
Stephen G. Holt, MBBS, PhD
Brighton and Sussex University Hospitals NHS Trust
Brighton BN2 5BE, United Kingdom
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IN RESPONSE: We appreciate Drs. Smith and Holt’s insightful com-
ments about the importance of assay characteristics and agree that
associations between particular measurements and outcome might be
influenced by the assay. Moreover, test specificity and reliability
might depend on factors present in the participants and specimens
being evaluated.
We used a fetuin-A assay developed by our group in Aachen,
Germany, which is not commercially available. This assay has been
described in greater detail in our prior articles (1) and was used
initially to show the associations of fetuin-A with mortality in pa-
tients with end-stage renal disease (2). We evaluated the nephelomet-
ric method for low fetuin-A serum measurement in a side-by-side
comparison with immunoblot analysis to exclude cross-reactivity of
the antibodies with other serum proteins and proteolytic fragments
of fetuin-A. We calculated final serum fetuin-A concentrations by
regression analysis of a serial dilution curve obtained from standard
serum. For comparison and reliability testing, we prepared a control
solution of purified serum fetuin-A powder (Boehringer Mannheim,
Mannheim, Germany, and Dade-Behring, Marburg, Germany). For
both methods, we used the polyclonal rabbit antihuman fetuin-A
antibody that does not cross-react with fetuin-B.
In regard to similarity in findings with other groups and assays,
we have shown that higher fetuin-A levels were associated with the
metabolic syndrome (1) and diabetes mellitus by using this assay.
Moreover, we have shown that lower fetuin-A levels were associated
with aortic stenosis, an association that was present only in partici-
pants without diabetes (3). These data are similar to findings from
Ford and colleagues (4) using the BioVendor fetuin-A assay (Bio-
Vendor, Candler, North Carolina). The study found lower fetuin-A
levels were associated with progression of arterial stiffness (potentially
a consequence of greater arterial calcium deposition), an association
that was also limited to persons without diabetes. Nonetheless, we
are uncertain of the correlation between our assay and that from
BioVendor. We agree that future studies with multiple assays may be
useful to show their correlations to one another and to determine
which has the strongest associations with arterial calcification, arterial
stiffness, and cardiovascular disease events in different settings.
Vincent M. Brandenburg, MD
University Hospital Aachen
D-52057 Aachen, Germany
Benjamin D. Parker, MD
Joachim H. Ix, MD, MAS
University of California, San Diego, and Veterans Affairs San Diego
Healthcare System
San Diego, CA 92161
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Urine Drug Testing Is Still an Invaluable Resource for
Primary Care
TO THE EDITOR: We commend Starrels and colleagues (1) for their
excellent systematic review and wholeheartedly agree that more rig-
orous studies are needed to determine the roles of treatment agree-
ments and urine drug testing (UDT) to reduce misuse of prescrip-
tion opioids. The authors could have emphasized, however, that in
addition to reducing opioid misuse, for which they found weak sup-
portive evidence, UDT plays an invaluable role in detecting abuse of
and addiction to prescribed opioids, illicit drugs, and nonprescribed
controlled substances, as well as diversion of prescribed opioids. The
abuse of prescription opioids in the United States has reached epi-
demic proportions. Heit and Gourlay (2), in their accompanying
editorial, point out that the number of new nonmedical users of
prescription opioids has equaled or exceeded the number of new
users of marijuana in recent years. The provenance of the opioids
and the consequences of their use were left unstated. As prescriptions
for opioid analgesics have increased dramatically in recent years,
there have been parallel increases in emergency department men-
tions, hospitalizations, and deaths related to these medications. In
fact, rates of poisoning mortality involving opioid analgesics have
been exponentially higher than those involving heroin and cocaine
(3). It should be sobering to all clinicians that most of the opioids
destined for nonmedical use in the United States originate from valid
physician prescriptions (4). Reducing misuse of prescription opioids
remains a vexing problem and depends on multiple patient, physi-
cian, and system factors. However, the utility of UDT in the detec-
tion of opioid-related problems is unequivocally supported by data,
such as the seminal study by Katz and colleagues (5), which shows
that UDT is perhaps the most important surveillance technique for
detecting illicit drug use in long-term opioid analgesic therapy.
Our concern is that the article by Starrels and colleagues, al-
though highlighting the dearth of quality evidence supporting the
role of UDT in reducing opioid misuse, devotes only a single sen-
tence to its role in detecting opioid and other substance use disor-
ders. As a result, it may provide yet another pretext for most primary
care physicians who prescribe opioid analgesics but never perform
drug testing (6) to continue not testing, thereby wasting valuable
opportunities to identify and address drug-related problems before
they end in tragedy.
Gary M. Reisfield, MD
Noni A. Graham, MPH
Mark S. Gold, MD
University of Florida College of Medicine
Gainesville, FL 32601
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IN RESPONSE: We agree with Dr. Reisfield and colleagues that UDT
is a valuable tool for monitoring patients receiving long-term opioid
therapy for chronic pain, but our endorsement of its use in primary
care is tempered by its limitations. Urine drug testing can detect use
of illicit or nonprescribed drugs that is not disclosed by patients,
which is essential to managing the risks associated with prescribed
opioids. When ordered and interpreted correctly, UDT can also de-
tect nonuse of prescribed opioids. However, although UDT detects
these 2 types of aberrant behavior, current evidence does not support
the claim that it can detect the clinical diagnoses of opioid use dis-
orders (that is, abuse and dependence) or the crime of diversion (that
is, selling or giving away). Indeed, Katz and colleagues’ article (1),
referenced by Dr. Reisfield and colleagues, found that UDT is effec-
tive in detecting “behaviors suggestive of inappropriate medication
use.” To detect the more serious outcomes of abuse, dependence, or
diversion, serial UDT results need to be interpreted over time along
with data from other sources, including patient interviews; physical
examination; pill counts; and monitoring of patient behaviors, such
as requests for early refills.
Although we highlight gaps in the scientific literature about
UDT, we agree that the public health threat posed by opioid misuse
is significant and that UDT may be useful for detecting proximal
outcomes (inappropriate drug use or nonuse). However, a study of
80 primary care physicians by Reisfield and colleagues (2) showed
that even those who performed UDT had poor knowledge of how to
interpret the results. Accurate interpretation of UDT results requires
an understanding of the type of assay ordered, major and minor
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opioid metabolic pathways, expected drug detection times, and po-
tential causes of false-positive and false-negative results. Misinterpre-
tation of these results can harm the physician–patient alliance or
patient well-being. For example, we are aware of physicians who
inappropriately discontinued synthetic opioids (that is, fentanyl) be-
cause they thought the negative results of an immunoassay-based
UDT for natural opiates (that is, morphine, codeine) signified evi-
dence of diversion. We recommend that physicians become better
educated about the use and limitations of UDT (3) and consult
their laboratory toxicologist with questions about which test to
order and how to interpret abnormal results. We also encourage
researchers to continue to investigate best practices regarding
UDT and other risk management strategies for patients who are
prescribed long-term opioids.
Joanna L. Starrels, MD, MS
Albert Einstein College of Medicine and Montefiore Medical Center
Bronx, NY 10467
Daniel P. Alford, MD, MPH
Boston University School of Medicine and Boston Medical Center
Boston, MA 02118
Barbara J. Turner, MD, MSEd
University of Pennsylvania School of Medicine
Philadelphia, PA 19134
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Guidelines and Conflicts of Interest
TO THE EDITOR: Guyatt and colleagues (1) group financial conflicts
of interest with intellectual conflicts of interest. I find this puzzling.
Financial conflicts of interest are of concern because they do not
coincide with and are not accountable to research or clinical aims.
But “intellectual conflicts of interest,” according to Guyatt and col-
leagues, are to be found in persons with substantive knowledge, en-
gagement, or research investment in the question at issue (indeed,
according to the authors’ view, they themselves would be disqualified
from primary authorship of any future expert guideline on intellec-
tual conflicts of interest). But those are precisely the people whose
opinions I want to hear.
The issue here is the misguided notion that evidence-based
medicine is the view from nowhere (2), a wholly objective enterprise
where evidence is weighed and summarized without contamination
by opinion. Evidence is never considered this way (3). Evidence-
based medicine depends on those who have thought-out, well-
informed opinions. It couldn’t be done without intellectual conflicts
of interest.
Better to define what makes intellectual content worthy of ex-
clusion (is it based on faulty data, suspicious borrowings, or retracted
publications?) than to try to eliminate what makes intellectual dis-
cussion possible: the strongly held opinions and long-term invest-
ment of experts.
Zackary D. Berger, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD 21205
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TO THE EDITOR: In the aftermath of the scandals over clinical guide-
lines written by experts with major conflicts of interest, Rothman
and colleagues (1) suggested that authors of guidelines of professional
medical associations be free of any financial conflicts of interest.
Guyatt and colleagues (2) have devised a complex solution to put
investigators with conflicts of interest back into action. Experts with
important financial conflicts can collect and interpret evidence, but
only panel members who are conflict-free can be involved in devel-
oping the recommendations for a specific question. Guyatt and col-
leagues say that investigators with conflicts of interest may offer
unique insights into the clinical context and evidence. No data, how-
ever, substantiate the claim that these experts are better qualified in
certain respects than those who chose to have no financial ties. In-
deed, Guyatt and colleagues anticipate that collection and interpre-
tation of findings may be potentially biased by conflicts of interest
but rely on methodologists, who have little or no clinical understand-
ing of the issues under discussion, for balancing the final outcome.
How will these methodological heroes circumvent subtle manipula-
tions and the unavoidable external pressures?
Rothman and colleagues (1) deserve credit for raising the issue
of intellectual conflicts of interest, which are part of the more general
problem of nonfinancial sources of conflict (3). However, the au-
thors do not set specific thresholds for all sorts of conflicts of interest.
I have outlined criteria for establishing the presence of a substantial
conflict (3), based on the work of Krimsky and colleagues (4): being
an employee of a private company, being a regular consultant or on
the board of directors of a company, being a stockholder of a com-
pany related to the field of research, or owning a patent directly
related to the published work. Occasional consultancies, grants for
performing investigations, or receiving honoraria or refunds in spe-
cific occasions would not be a source of substantial conflict. Simi-
larly, there are several steps for setting a threshold to and addressing
nonfinancial conflicts of interest in medical research (3).
Are guidelines necessary? Guyatt and colleagues argue that with-
out them, clinicians would have to undertake their own reviews. I
agree that spending nights performing meta-analyses for deciding
what to prescribe the next morning would be unrealistic. But re-
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views, case management articles, and updates were available in the
medical literature well before guidelines became fashionable. In jour-
nals that claim independence, guidelines should be reserved for in-
vestigators without substantial conflicts of interest (3). Actually, the
problem of guidelines and conflicts of interest is only part of the
general problem of professional medical organizations. I have out-
lined some suggestions for fostering creativity and independence in
professional medical organizations (3), such as complete change of
leadership and inclusion of physicians who are not experts in the
specific field. Unless profound changes occur, professional medical
organizations may no longer have the credibility for issuing guide-
lines. What credibility is left (and it is not much) should not be
put at risk, because when trust goes, so does the healing power of
physicians (5).
Giovanni A. Fava, MD
University of Bologna
40127 Bologna, Italy
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IN RESPONSE: Dr. Berger wants to hear the opinions of authors with
intellectual conflicts of interest. We agree, which is why we ensure
the active engagement of these experts in the process of gathering,
summarizing, and interpreting the evidence used in our guidelines.
Dr. Fava implies that we should be recruiting experts without
financial conflicts of interest to our guideline panels. In areas of
investigation in which most world leaders are free of financial con-
flicts, this may be a good idea. However, in several areas, including
thrombosis, many of the international authorities have financial con-
flicts. Excluding them from gathering and interpreting the evidence
would result in lower-quality guidelines.
Dr. Fava suggests that our methodologist chapter editors have
“little or no clinical understanding of the issues under discussion,”
which shows insufficient respect for the capacity of intelligent scien-
tists to, after detailed review and discussion of the evidence with
leaders in the field, understand the relevant clinical issues. Neverthe-
less, we agree that clinical expertise is important for optimum under-
standing. That is why, among our 13 methodologist chapter editors,
we have recruited 10 specialists in internal medicine, 1 surgeon, and
1 primary care physician, and why the 3 methodologist editors with
ultimate responsibility for the guidelines are also specialists in inter-
nal medicine. Other organizations (the World Health Organization
[1], the Allergic Rhinitis and Its Impact on Asthma guideline panel
[2], and the World Allergy Organization [3]) have successfully placed
major responsibility on nonexpert clinician-methodologists in recent
guidelines.
Dr. Fava notes that we did not provide specific thresholds for all
sorts of conflicts of interest and cites guidelines from his own and others’
work. We do have detailed criteria; however, the word count limitations
of the article prevented their presentation in the Annals, but they are
available for anyone interested (e-mail, guyatt@mcmaster.ca).
Dr. Fava challenges the need for practice guidelines. The pop-
ularity of recommendations to guide practice attests to their neces-
sity. Formal structured processes of recruiting panelists with meth-
odological and content expertise; summarizing and interpreting
evidence regarding desirable and undesirable consequences of alter-
native management strategies; summarizing and interpreting evi-
dence regarding patients’ values and preferences; specifying the pref-
erences underlying recommendations; and developing and applying
rules for participation in decision making that consider financial and
intellectual conflicts of interest are certain to result in higher-quality
recommendations. Investigation addressing the effect of financial and
intellectual conflicts and associated guideline policies could inform
what is certain to be an ongoing debate.
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CLINICAL OBSERVATION
A Rare Cause of Cardiac Ischemia: Systemic Lupus
Erythematosus Presenting as the Hyperviscosity Syndrome
Background: The hyperviscosity syndrome can cause cardiac
ischemia by impairing microcirculation. This syndrome with cardiac
ischemia can be caused by erythrocytosis, leukocytosis, hypercholes-
terolemia, or paraproteinemia (1). The hyperviscosity syndrome
from paraproteinemia more commonly results from the monoclonal
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gammopathies of multiple myeloma and Waldenstro¨m macroglobu-
linemia and less commonly from the polyclonal gammopathies of
rheumatoid arthritis, the Sjo¨gren syndrome, chronic hepatitis, and
some rare lymphoproliferative disorders (2). To the best of our knowl-
edge, only 3 case reports (3–6) have described the hyperviscosity
syndrome in systemic lupus erythematosus (SLE), and only 1 of
these reports (6) described hyperviscosity as the initial manifestation.
Objective: To describe cardiac ischemia from the hyperviscosity
syndrome in a patient with previously undiagnosed SLE.
Case Report: We accepted transfer to our cardiac intensive care
unit of a 47-year-old African-American woman with chest pain and
dyspnea whose physicians suspected the acute coronary syndrome.
Her presentation was atypical because she had recurrent chest pain
and dyspnea for 2 months but new onset of left ankle pain, dizziness,
and blurry vision. Two months before transfer, her physicians diag-
nosed anemia, cardiomyopathy with an ejection fraction of 0.35,
biventricular hypertrophy, pulmonary hypertension, and polyclonal
IgG gammopathy of undetermined origin.
On admission to the intensive care unit, she seemed weak and
tired. She was afebrile and normotensive, with a heart rate of 80
beats/min. She reported scalp alopecia and a 100-lb weight loss dur-
ing the past year. On examination, we found clear lungs, a loud P2,
a tender left ankle without swelling or erythema, intact extraocular
movements, and normal visual acuity. Electrocardiography revealed
normal sinus rhythm, no chamber enlargement, and nonspecific
T-wave inversions. The phlebotomist noted the patient’s blood to
be “thick,” because the initial blood samples clotted. Initial lab-
oratory studies included elevated troponin I (0.10 ng/mL) and
paraprotein (nonalbumin protein, 10.5 g/dL) levels. The patient’s
plasma viscosity ratio was 16.0 (plasma–saline), and we initiated
emergency plasmapheresis for the hyperviscosity syndrome.
Although our patient had ankle pain, she did not have the
morning stiffness or joint pain characteristic of rheumatoid arthritis.
She also did not have the keratoconjunctivitis sicca and xerostomia
characteristic of the Sjo¨gren syndrome. An inguinal lymph node
biopsy with flow cytometry ruled out lymphoproliferative disorders.
Table. Laboratory Values at Admission and Serial
Measurements of Cardiac Enzymes and Plasma Viscosity
Admission Hematology Panel Value
Leukocyte count (range),  109 cells/L 4.5 (4.5 to 11.0)
Hemoglobin level (range), g/L 97 (120 to 160)
Hematocrit (range), % 28.4 (37 to 48)
Platelet count (range),  109 cells/L 117 (150 to 350)
Leukocyte differential (range), %
Lymphocytes 46 (24 to 44)
Monocytes 13 (2 to 11)
Neutrophils 39 (40 to 70)
Immature granulocytes 0.2 (0.0 to 0.1)
Eosinophils 1.3 (1 to 4)
Basophils 0.2 (0.0 to 2.0)
Reticulocytes 1.5 (0.5 to 1.8)
Prothrombin time (range), s 15.5 (9.6 to 11.5)
Activated partial prothrombin time (range), s 33.0 (22.8 to 33.3)
International normalized ratio (range) 1.5 (0.9 to 1.1)
ESR (range), mm/h 130 (4 to 25)
C-reactive protein (range), nmol/L 0.29 (0.0 to 0.48)
Admission Complete Metabolic Panel Value
Sodium level (range), mmol/L 131 (135 to 148)
Potassium level (range), mmol/L 4.0 (3.5 to 5.1)
Chloride level (range), mmol/L 104 (96 to 109)
Bicarbonate level (range), mmol/L 23 (21 to 31)
Glucose level (range)
mmol/L 6.4 (3.33 to 5.49)
mg/dL 116 (60 to 99)
Blood urea nitrogen level (range), mmol/L 8.6 (2.5 to 7.9)
Creatinine level (range)
mmol/L 97.24 (44.2 to 106.1)
mg/dL 1.1 (0.5 to 1.2)
Calcium level (range)
mmol/L 2.1 (2.1 to 2.6)
mg/dL 8.5 (8.4 to 10.5)
Phosphate level (range)
mmol/L 1.6 (0.87 to 1.5)
mg/dL 5.1 (2.7 to 4.5)
Magnesium level (range)
mEq/L 0.85 (0.65 to 1.0)
mg/dL 1.7 (1.3 to 2.0)
Total protein level (range), g/L 129 (60 to 82)
Albumin level (range), g/L 24 (35 to 53)
Aspartate aminotransferase level (range), U/L 82 (0 to 31)
Alanine aminotransferase level (range), U/L 41 (0 to 31)
Alkaline phosphatase level (range), U/L 43 (30 to 120)





24 h (after first plasmapheresis) 6.0
2 d 6.0





Time of Serial Cardiac Enzyme Measurement Value
Admission
CK-MB fraction, g/L* –
CK index, %† –
Troponin I level, ng/mL‡ 0.10
14 h
CK-MB fraction, g/L* 12
CK index, %† 4
Troponin I level, ng/mL‡ 0.14
18 h (after first plasmapheresis)
CK-MB fraction, g/L* 14
CK index, %† 4
Troponin I level, ng/mL‡ 0.13
3 d
CK-MB fraction, g/L* 15
CK index, %† 5
Troponin I level, ng/mL‡ 0.08
5 d (after second plasmapheresis)
CK-MB fraction, g/L* 18
CK index, %† 5
Troponin I level, ng/mL‡ 0.14
CK-MB  creatine kinase–MB; ESR  erythrocyte sedimentation rate.
* Range, 0 to 7.
† Range, 0 to 3.
‡ Range, 0.00 to 0.06.
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She had positive test results for antinuclear antibodies (ANA) (titer,
640), rheumatoid factor, anti–double-stranded DNA (anti-dsDNA),
antiribonucleoprotein antibodies, and anti–68-kD antibodies. Her
C3 and C4 levels were within normal limits. We diagnosed SLE on
the basis of her alopecia, anemia, positive ANA results, and positive
anti-dsDNA results.
Her physicians discharged her from the hospital 10 days later
with prescriptions for dexamethasone, warfarin, and sulfamethoxazole–
trimethoprim in addition to her admitting medications. She did not
take her medications as they were prescribed; developed worsening
headaches, dizziness, and difficulty sleeping 6 months later; and was
admitted to another hospital for recurrent hyperviscosity syndrome.
Her condition is currently maintained successfully with prednisone
therapy.
Discussion: Patients with the hyperviscosity syndrome can
present with constitutional, neurologic, and cardiovascular symp-
toms (2). Symptoms are not expected until plasma viscosity in-
creases above a plasma–saline ratio of 4.0:5.0. Immediate plasma-
pheresis reduces the risk for neurologic complications, and 75%
of patients with plasma viscosities greater than 5.0 have reduc-
tions in neurologic and other symptoms with plasmapheresis (3).
Our patient required 2 sessions of plasmapheresis to reduce
plasma viscosity to 2.7.
Non–ST-elevation cardiac ischemia can occur in the acute
coronary syndrome, subendocardial ischemia, coronary artery dis-
section, coronary artery vasospasm, coronary embolism, and the
hyperviscosity syndrome. We believe that hyperviscosity was the
sole cause of our patient’s cardiac ischemia, because she had a
relatively mild troponin I elevation and cardiac enzyme levels and
symptoms returned to normal when plasmapheresis reduced the
viscosity ratio (Table).
Conclusion: Our patient had cardiac ischemia caused by a hy-
perviscosity syndrome from the paraproteinemia of SLE.
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